The global absorbable hydrogel tissue spacer market, used primarily in prostate cancer radiation therapy, is gaining momentum as healthcare providers increasingly adopt technologies designed to reduce treatment side effects while improving patient outcomes.

Industry analysts estimate the market will grow from approximately $393.6 million in 2025 to about $851 million by 2030, representing a compound annual growth rate of roughly 16–17%.

Hydrogel spacers are injected between the prostate and rectum during radiation therapy, temporarily creating space between organs. This separation can reduce radiation exposure to the rectum by up to 70%, allowing physicians to deliver more precise and higher-dose cancer treatments while preserving patient quality of life.

Growth in the sector is being supported by several trends, including rising prostate cancer incidence, increased use of precision radiation therapy, and expanding use of hydrogel spacers across additional cancers such as cervical, bladder, breast, and esophageal tumors.

Boston Scientific (NYSE: BSX) Leads the Market

Boston Scientific Corporation (NYSE: BSX) remains the dominant player in the hydrogel spacer category through its flagship SpaceOAR™ Hydrogel and SpaceOAR Vue™ technologies.

Since receiving FDA clearance in 2015, more than 220,000 SpaceOAR units have been deployed globally. The product is supported by over 225 peer-reviewed publications and clinical data demonstrates approximately 73% reduction in rectal radiation dose.

SpaceOAR is widely integrated into urology and radiation oncology workflows, helping drive adoption across major cancer treatment centers. Technology is part of Boston Scientific’s broader urology and oncology portfolio, which contributes to the company’s diversified $100+ billion medical technology platform spanning cardiology, endoscopy, neuromodulation, and oncology devices.

Teleflex (NYSE: TFX) Expands Competition with Barrigel™

Teleflex Incorporated (NYSE: TFX) entered the market following its 2022 acquisition of Palette Life Sciences, which developed Barrigel™, a hyaluronic acid-based spacer.

Barrigel remains pliable and sculptable longer than PEG-based hydrogels, allowing physicians greater customization during placement. Clinical data suggests comparable rectal protection, positioning Teleflex as a growing competitor, particularly in cost-sensitive healthcare systems.

Accuray (NASDAQ: ARAY) Adds Ecosystem Synergies

Accuray Incorporated (NASDAQ: ARAY) participates in the ecosystem through its CyberKnife® robotic radiosurgery platform, widely used in stereotactic body radiation therapy (SBRT).

Hydrogel spacers enable physicians using CyberKnife to tighten treatment margins and safely escalate radiation doses, improving precision and patient safety. Rather than competing directly with spacer developers, Accuray benefits from technology synergies within radiation oncology workflows.

CS Diagnostics (OTCQB: CSDX) Emerging as an Innovator

At the micro-cap level, CS Diagnostics Corp. (OTCQB: CSDX) is developing CS-Protect Hydrogel, a ready-to-use spacer designed to eliminate the mixing steps required by some competing products.

The company is also exploring broader applications beyond prostate cancer, including cervical, esophageal, bladder, and breast radiation therapy.

Recent milestones include U.S. patent filings, manufacturing partnerships in early 2026, and financing to support commercialization efforts. With a market capitalization estimated between $20 million and $45 million, CS Diagnostics represents a high-risk, early-stage entrant within the expanding hydrogel spacer market.

ENDRA Life Sciences (NASDAQ: NDRA) Targets MASH and GLP-1 Healthcare Ecosystem

ENDRA Life Sciences (NASDAQ: NDRA) is emerging as a compelling story in the rapidly expanding MASH and GLP-1 healthcare ecosystem, where the need for scalable diagnostics is becoming increasingly urgent.

As pharmaceutical companies race to develop therapies for metabolic dysfunction–associated steatohepatitis (MASH) and related steatotic liver disease (SLD)—conditions affecting more than two billion people globally—healthcare systems face a major challenge: identifying and monitoring millions of patients efficiently.

ENDRA’s TAEUS® (Thermo-Acoustic Enhanced UltraSound) technology is designed to address this gap by enabling non-invasive liver fat measurement at the point of care, potentially delivering MRI-level insights at a fraction of the cost. With GLP-1 therapies accelerating screening and long-term monitoring needs, scalable liver imaging solutions like TAEUS could play an increasingly important role in supporting the next phase of metabolic disease management.

Outlook for the Sector

Analysts remain optimistic about the long-term growth of hydrogel tissue spacers as radiation oncology moves toward precision medicine and patient-centered treatment approaches.

While Boston Scientific (NYSE: BSX) continues to lead the category through strong clinical evidence and physician adoption, competitors such as Teleflex (NYSE: TFX), Accuray (NASDAQ: ARAY), emerging innovators like CS Diagnostics (OTCQB: CSDX) and outliners such as ENDRA Life Sciences (NASDAQ: NDRA) are helping expand the overall market.

As demand for advanced prostate cancer treatment technologies grows globally, hydrogel spacers are expected to remain one of the fastest-growing segments within the broader radiation oncology and medical device sectors.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com